Rising depression prevalence is expected to drive growth in the global treatment resistant depression market over the forecast period. For example, the Journal of Clinical Psychiatry published an article in 2021 stating that in the United States, 8.9 million people were treated for major depression and nearly 2.8 million people had treatment-resistant depression.
Furthermore, rising generic product launches by major players are expected to drive growth in the global treatment resistant depression market over the forecast period. Dr. Reddy's Laboratories Ltd., for example, announced the release of Bupropion Hydrochloride Extended-Release Tablets in September 2019. These are generic versions of Zyban Extended-Release Tablets that have been approved by the US Food and Drug Administration.
Read More:
https://knackersblogger.blogspot.com/2022/12/treatment-resistant-depression-market.html
